



Dynavax to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference

BERKELEY, Calif., April 6, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Michael Ostrach, Chief Business Officer, will present an overview of the company at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York City. Mr. Ostrach is scheduled to present on Wednesday, April 11 at 8:00 a.m. Eastern Daylight Savings Time. The presentation will be webcast.

To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at <http://www.dynavax.com> under the "Investors" section.

ABOUT DYNAX

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our pipeline includes: HEPLISAV(TM), a hepatitis B vaccine in Phase 3; TOLAMBA (TM), a ragweed allergy immunotherapeutic; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for Hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. NIH partially funds our preclinical work on a vaccine for influenza; Symphony Dynamo, Inc., funds our colorectal cancer and hepatitis B therapy trials and our preclinical hepatitis C therapeutic program. While the NIH and Symphony provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit <http://www.dynavax.com>.

SOURCE Dynavax Technologies Corporation

Shari Annes, Investor Relations of Dynavax Technologies Corporation, +1-650-888-0902, sannes@dynavax.com

<http://www.dynavax.com>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX